Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gas–liquid interface in the intestinal lumen is the physical boundary where gastrointestinal gases, such as nitrogen, hydrogen, and carbon dioxide, meet the liquid mucus and chyme within the digestive tract (StatPearls, 2023). Under normal physiological conditions, gas is passed efficiently; however, in various gastrointestinal disorders, gas can become trapped in a stable, fine foam, leading to clinical symptoms like bloating, distension, and abdominal pain (PubMed, PMID: 24106601). This interface acts as a physicochemical target for anti-foaming agents, most notably simethicone, which is a mixture of polydimethylsiloxane and silica gel (PubChem, CID: 6433516). These drugs do not interact with traditional biological receptors or enzymes but instead lower the surface tension at the gas-liquid boundary, causing small, trapped bubbles to coalesce into larger ones that are more easily eliminated via eructation or flatulence (DrugBank, DB09512). Targeting this interface is a standard approach for the symptomatic treatment of functional dyspepsia, irritable bowel syndrome, and postoperative gas distress. Additionally, modifying this interface is clinically significant for improving mucosal visualization during diagnostic procedures like endoscopy or ultrasound by removing obscuring foam (NIH, 2022).
Reduction of surface tension at the gas-liquid interface, facilitating the coalescence of small, trapped bubbles into larger ones that are more easily expelled via eructation or flatus (StatPearls, 2023).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gas–liquid interface in the intestinal lumen.